Stock Ratings / Health Care / PMN / insiders

MIST (47) PMVP (45) GNLX (29) VTVT (33) ⌘ Pro Terminal →

ProMIS Neurosciences Inc. (ON) (PMN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is PMN trading relative to its 50-day, 200-day, and 52-week technical levels?

PMN last traded at $3.31 (-70.13% on volume of 1,639,844 shares), positioning the stock -69.99% below its 50-day simple moving average ($11.03) and -74.28% below its 200-day simple moving average ($12.87). Across its 52-week range of $2.84 to $27.40, PMN sits at the 1.9% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

Q: Are PMN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PMN leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$3.31 -70.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.89

ProMIS Neurosciences Inc. (ON) (PMN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $99.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PMN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ProMIS Neurosciences Inc. (ON) (NASDAQ: PMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.31 (-70.13% 1D, market cap $99.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMN ranks #529 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PMN compare to MIST and PMVP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and PMVP (PMV Pharmaceuticals Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $101.9M). Among the 5-stock peer group, PMN leads on earnings multiple (N/A) while PMN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PMN?

▼

Per PMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374339), ProMIS Neurosciences Inc. (ON) generated $0 in revenue, -$39.7M in net income, and -$28.1M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.89 (-12.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY PMN SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.45-12.9% Next Q

Q2 (-2Q)

Grade D$8.23-2.1% Next Q

Q3 (-1Q)

Grade D$8.06-58.9% Next Q

Current

Grade D-$3.31-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PMN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PMN currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.03) and Max Pain ($3.48) forces dealer call-delta covering toward $28.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PMN Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PMN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PMN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMN)

✓Walkthrough of PMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.10%▼ SUPPORT BREAKDOWN

2026-11-02O $3.59H $4.50L $2.84C $3.31VOL 3.13M

RES: $11.97SUP: $7.31SMA50: $11.03SMA200: $12.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMN Butterfly Map → + Track PMN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMN)

Health Care Rank #529 of 1016 ⚔️ MIST vs PMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMN vs. MIST, PMVP, GNLX, VTVT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ProMIS Neurosciences Inc. (ON) (PMN) ranks #529 by composite RQD confidence (40/100, grade D-) and #662 by equity capitalization ($99.4M). Within this direct 5-issuer industry benchmark cohort, PMN leads on earnings valuation at N/A trailing P/E, while PMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MIST currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PMN at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMN ACTIVE ProMIS Neurosciences Inc. (ON)	D-	40/100	—	—	-35.0%	-70.13%	$99.4M	Benchmark Subject
MIST Milestone Pharmaceuticals Inc.	D	47/100	—	—	-35.0%	-7.55%	$98.3M	/mist-vs-pmn →
PMVP PMV Pharmaceuticals Inc.	D	45/100	—	—	-35.0%	-2.96%	$101.9M	/pmvp-vs-pmn →
GNLX Genelux Corporation	E	29/100	—	—	-35.0%	-0.95%	$95.0M	/gnlx-vs-pmn →
VTVT vTv Therapeutics Inc. (Class A)	E	33/100	—	—	-35.0%	-4.59%	$104.3M	/vtvt-vs-pmn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001374339

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProMIS Neurosciences Inc. (ON) (PMN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.7M, operating cash flow of -$28.1M, and free cash flow of -$28.1M (-3.4% YoY). On the balance sheet, PMN closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$39.7M	-$28.1M	-$28.1M	$9.2M	—
FY2024 (FY)	2024-12-31	$0	$2.8M	-$27.2M	-$27.2M	$18.9M	—
FY2023 (FY)	2023-12-31	$0	-$13.2M	-$10.8M	-$10.8M	—	—

3. PMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PMN compare to MIST and PMVP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PMN?

Where is PMN trading relative to its 50-day, 200-day, and 52-week technical levels?

PMN last traded at $3.31 (-70.13% on volume of 1,639,844 shares), positioning the stock -69.99% below its 50-day simple moving average ($11.03) and -74.28% below its 200-day simple moving average ($12.87). Across its 52-week range of $2.84 to $27.40, PMN sits at the 1.9% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

PMN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PMN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PMN leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: PMN RQD Cockpit PMN 12M Forecast PMN Earnings & Move PMN Dividends & DRIP PMN Insiders & 13F PMN Whale Options PMN Profit Sankey PMN News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PMN — ProMIS Neurosciences Inc. (ON): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PMN scores 40 out of 100, a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow, so valuation cannot be anchored to earnings or cash generation.
Whale / 13F Flow: 7 / 20. The source describes this pillar as covering institutional accumulation and options positioning, but no 13F or options detail is provided in the holders or analyst sections. The low score signals weak institutional support as captured by this model.
Insider Conviction: 5 / 20. The RQD rating references SEC Form 4 and Congressional PTR cluster flow. The score is among the weakest pillars, indicating limited insider-side conviction in the data available.
Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. A prospective investor should recognize that the stock moves in line with the broad market and offers no defensive buffer from this factor alone.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1 of 9, and Debt/Equity is 0.5. The weak Piotroski reading points to deteriorating fundamentals, while the Altman figure sits in a zone that warrants caution.

Taken together, the pillar scores indicate that the primary drag is the absence of cash generation and the weak forensic profile. Upside would require a clear improvement in operating economics, which the source data does not show. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable.

Business

ProMIS Neurosciences Inc. (ON) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company carries a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M across the periods provided.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-40.2M	$-39.7M	N/A	$-28.1M	$6.1M	N/A
FY 2024	$0.0M	$-16.8M	$2.8M	N/A	$-27.2M	$13.3M	N/A
FY 2023	$0.0M	$-14.3M	$-13.2M	N/A	$-10.8M	N/A	N/A

Per the SEC financials, operating losses widened from $-14.3M in FY 2023 to $-40.2M in FY 2025, and reported revenue is $0.0M in every period. Gross, operating, and net margins are each recorded as 0% in the market data. The source reports ROIC of -35%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 1/9. Cash declined from $13.3M to $6.1M between FY 2024 and FY 2025, and debt is not reported.

Open Questions

What products or pipeline assets generate the company's business, and what are their development stages?
Given the reported cash balance of $6.1M against an FY 2025 FCF of $-28.1M, what is the funding runway and financing plan?
What drove the FY 2024 net income of $2.8M when operating income was $-16.8M, and is that result recurring?
What debt obligations exist, since the debt field is not reported in any period?
What institutional and insider holdings underlie the RQD flow pillars, given that the holders section is empty?

PMN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ProMIS Neurosciences Inc. (ON) (PMN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PMN Debate Forum (3) ↓

🟡 MARKET WIRE Benzinga • 3d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 3d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics

Read Full Source ↗

🟢 CATALYST Yahoo • 4d ago

Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade

The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?

HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?

Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PMN Bull vs. Bear Conversation Board — What's Your Call at $3.31?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.75 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PMN (D- • RQD 40/100) a Buy at $11.08?

Welcome to the PMN (ProMIS Neurosciences Inc. (ON)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.75 (-21.0%)

Spot @ $11.08

Pump the brakes on PMN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PMN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ProMIS Neurosciences Inc. (ON) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.63 (+14.0%)

Spot @ $11.08

PMN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PMN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.08 (52-wk range $10.24 - $12.68), any beat on forward guidance forces shorts and underweight funds to chase.